The best Bull and Bear pitches based on recency and number of recommendations.
I'm as skeptical as anyone about the long-term prospects of Medgenics. For a technology as groundbreaking as the Biopump would seem to be, there doesn't seem to be much excitement coming from anyone except management. And if the company does indeed… More
Medgenics is making slow progress with their rather dubious Biopump platform. Enrollment has begun in the phase I/II trial of Infradure for hepatitis C in Israel, but interim data doesn't seem to have appeared in late 2013 as promised. And really,… More
Read the most recent pitches from players about GNMX.DL.
Find the members with the highest scoring picks in GNMX.DL.
See what the Wall Street professionals think, according to their public statements and filings.